Pharming Group N.V. Stock Analysis & AI Score
Pharming Group N.V. (PHAR) has an ST Score of 46.9 (C+), driven by its Profitability (A+) and held back by its Valuation (D-). Analysts rate it Buy with a $39.00 price target (+273.6% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Pharming Group N.V. (PHAR) has an ST Score of 46.9 (C+), driven by its Profitability (A+) and held back by its Valuation (D-). Analysts rate it Buy with a $39.00 price target (+273.6% upside).
- Strongest
- ProfitabilityA+
- Weakest
- ValuationD-
All factor grades
- ProfitabilityA+
- ForecastA
- MomentumC-
- GrowthC-
- Financial StrengthD
- ValuationD-
- Piotroski5/9
Contact
PHAR stock: frequently asked questions
What is PHAR's ST Score?
Pharming Group N.V. (PHAR) has an ST Score of 46.9 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is PHAR a buy, hold, or sell?
Analysts rate PHAR a Buy, with a price target of $39.00 (+273.6% vs the current price). Our ST Score grades it C+ (46.9/100). The ST Score is a data-driven signal, not a recommendation.
What are PHAR's factor grades?
Valuation D-, Profitability A+, Financial Strength D, Momentum C-, Growth C-, Forecast A.
What is PHAR's valuation grade?
Pharming Group N.V. (PHAR) earns a valuation grade of D-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is PHAR's growth grade?
Pharming Group N.V. (PHAR) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is PHAR's profitability grade?
Pharming Group N.V. (PHAR) earns a profitability grade of A+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is PHAR's financial strength grade?
Pharming Group N.V. (PHAR) earns a financial strength grade of D, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for PHAR?
The average analyst price target for Pharming Group N.V. (PHAR) is $39.00 from 3 analysts, which is +273.6% versus the recent price of $10.44.
What is PHAR's Piotroski score?
Pharming Group N.V. (PHAR) has a Piotroski F-Score of 5 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.